Sam Brusco, Associate Editor10.02.23
Boston Scientific has launched its LUX-Dx II+ insertable cardiac monitor (ICM), its next-gen ICM for long term monitoring of arrhythmias linked to atrial fibrillation (AFib), cryptogenic stroke, and syncope.
The ICM features dual-stage algorithms that spot, then verify potential arrhythmias before an alert is sent to clinicians to offer actionable data. The device also has remote programming to adjust event detection settings and record systems, without needing an in-person appointment.
The company said the dual-stage algorithms can be programmed to identify episodes of AFib, atrial and ventricular tachycardia, bradycardia, and rhythm pause. A new premature ventricular contraction (PVC) burden algorithm help LUX-Dx II+ spot arrythmias when established thresholds or parameters are exceeded.
Further verification filter levels are then applied. Additional options for nighttime programming specific to bradycardia and pause episodes are also included, which the company hopes will help reject false positive detections and irrelevant episodes.
A new downloadable app option also aims to make remote monitoring more convenient and seamless.
“The LUX-Dx II+ ICM System builds on a strong foundation of cardiac diagnostic technologies at Boston Scientific to provide care teams with the necessary data for critical decision making,” Scott Olson, senior VP and president, Cardiac Rhythm Management and Diagnostics, Boston Scientific, told the press. “With enhanced and new diagnostic algorithms, physicians will receive timely, accurate and actionable insights to help them make clinically meaningful decisions.”
The company’s latest-generation WATCHMAN FLX Pro left atrial appendage closure (LAAC) device earned FDA approval last month.
The ICM features dual-stage algorithms that spot, then verify potential arrhythmias before an alert is sent to clinicians to offer actionable data. The device also has remote programming to adjust event detection settings and record systems, without needing an in-person appointment.
The company said the dual-stage algorithms can be programmed to identify episodes of AFib, atrial and ventricular tachycardia, bradycardia, and rhythm pause. A new premature ventricular contraction (PVC) burden algorithm help LUX-Dx II+ spot arrythmias when established thresholds or parameters are exceeded.
Further verification filter levels are then applied. Additional options for nighttime programming specific to bradycardia and pause episodes are also included, which the company hopes will help reject false positive detections and irrelevant episodes.
A new downloadable app option also aims to make remote monitoring more convenient and seamless.
“The LUX-Dx II+ ICM System builds on a strong foundation of cardiac diagnostic technologies at Boston Scientific to provide care teams with the necessary data for critical decision making,” Scott Olson, senior VP and president, Cardiac Rhythm Management and Diagnostics, Boston Scientific, told the press. “With enhanced and new diagnostic algorithms, physicians will receive timely, accurate and actionable insights to help them make clinically meaningful decisions.”
The company’s latest-generation WATCHMAN FLX Pro left atrial appendage closure (LAAC) device earned FDA approval last month.